Freddy A. Jimenez - Feb 13, 2024 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP & GENERAL COUNSEL
Signature
/s/ Sam Martin, attorney-in-fact for Freddy A. Jimenez
Stock symbol
CLDX
Transactions as of
Feb 13, 2024
Transactions value $
$93,163
Form type
4
Date filed
2/15/2024, 04:05 PM
Previous filing
Jun 20, 2023
Next filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $37.6K +4.17K +236.97% $9.02 5.92K Feb 13, 2024 Direct F1, F2
transaction CLDX Common Stock Options Exercise $55.6K +20K +337.61% $2.78* 25.9K Feb 13, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -4.17K -100% $0.00* 0 Feb 13, 2024 Common Stock 4.17K $9.02 Direct F1, F3
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -20K -100% $0.00* 0 Feb 13, 2024 Common Stock 20K $2.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 62,500 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
F2 Includes 1,328 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
F3 As of June 13, 2022, the option is fully vested.
F4 As of June 19, 2023, the option is fully vested.